+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of intraperitoneal chemotherapy in stage IV gastrointestinal cancer



Evaluation of intraperitoneal chemotherapy in stage IV gastrointestinal cancer



Zhonghua Zhong Liu Za Zhi 23(1): 67-69



To evaluate the short term and long term therapeutic effects of intraperitoneal versus intravenous chemotherapy in 56 cases with stage IV gastrointestinal cancer. The patients were randomly divided into two groups: 35 cases in the intraperitoneally treated group and 21 cases in the intravenously treated group. The short term effects and side effects were observed. The survival time of the patients was also recorded. The survival function was estimated by Kaplan-Meier method, and the significance test was done by Log rank method. There was no significant difference between the two groups in short term effects, and liver and kidney damages. Nausea, vomiting and bone marrow suppression were more severe in the intravenously treated group, while abdominal distension and pain were the major side effects in the intraperitoneally treated group. The median survival time and one year survival rate of patients in the intraperitoneally treated group were higher than those in the intravenously treated group. For patients with stage IV gastrointestinal cancer, intraperitoneal administration of chemotherapeutic agents is a better treatment of choice.

(PDF emailed within 1 workday: $29.90)

Accession: 046010748

Download citation: RISBibTeXText

PMID: 11783075


Related references

Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecologic Oncology 112(3): 444-449, 2009

Intraperitoneal (Ip) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: clinical evaluation and pharmacokinetics. Gan No Rinsho. Japan Journal of Cancer Clinics 34(2): 191-195, 1988

Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bulletin du Cancer 97(4): E23-E32, 2010

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecologic Oncology 100(1): 27-32, 2005

Re: intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecologic Oncology 102(1): 129; Author Reply 130-129; Author Reply 130, 2006

Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. Gynecologic Oncology 142(1): 13-18, 2016

David Oliver: Accountability-individual blame versus a "just culture". Bmj 361: K1802-K1802, 2018

Intraperitoneal chemotherapy for stage III ovarian cancer. Journal of Clinical Oncology 21(5): 957; Author Reply 957-8, 2003

Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer. Surgery Today 44(12): 2209-2220, 2015

Combination of intraperitoneal hyperthermic perfusion chemotherapy (IHPC) with intraperitoneal chemotherapy as a treatment modality for persistent ovarian cancer. European Journal of Gynaecological Oncology 28(2): 128-130, 2007

A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. Gynecologic Oncology 134(3): 468-472, 2014

Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. Gynecologic Oncology 143(3): 496-503, 2016

Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy. Oncology 18(2): 207-19; Discussion 220-2, 227-8, 230, 2004

Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Seminars in Oncology 16(4 Suppl 6): 83-97, 1989

Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. American Surgeon 66(6): 561-568, 2000